Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML

(2012) Florian H. Heidel et al.   Cell Stem Cell

Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data

(2012) Susanne Schnittger et al.   GENES CHROMOSOMES & CANCER

Molecular analysis of differentFLT3-ITD mutations in acute myeloid leukemia

(2012) Olga Blau et al.   LEUKEMIA & LYMPHOMA

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Long FLT3 internal tandem duplications and reduced PML-RAR  expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients

(2010) M. C. Chillon et al.   HAEMATOLOGICA

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

(2009) S. Kayser et al.   BLOOD

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

(2008) F. Breitenbuecher et al.   BLOOD

An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML

(2008) L. Bullinger et al.   BLOOD